One study rarely unlocks full payer coverage. Learn why U.S. market access requires a portfolio of evidence, strategic sequencing, and payer-specific insights.
Why do better technologies struggle for reimbursement while outdated ones thrive? Discover the hidden bias in payer decision-making—and why second movers in MedTech face steeper evidence hurdles than the first.